February 7th 2022, 2:20pm
Panelists look toward the future management of myelodysplastic syndromes with respect to novel agents and treatment pathways.
February 7th 2022, 2:00pm
Experts reflect on interchangeability between oral and intravenous therapy in patients with higher-risk myelodysplastic syndromes.
January 31st 2022, 2:20pm
Practical considerations for managing patient adherence on an oral therapy for higher-risk myelodysplastic syndromes.
January 31st 2022, 2:00pm
Shared insight on the historical and current use of hypomethylating agents in patients with myelodysplastic syndromes.
Perspectives on the use of oral HMA therapy in higher-risk myelodysplastic syndromes, and how this has improved patient care.
January 24th 2022, 2:20pm
Expert panelists discuss when it’s appropriate to consider or continue ESA therapy or blood transfusions in patients with MDS.
January 24th 2022, 2:00pm
Panelists share insight on therapeutic goals when treating patients with myelodysplastic syndromes.
January 17th 2022, 2:20pm
A brief review of disease and patient factors that influence the selection of therapy for myelodysplastic syndromes.
January 17th 2022, 2:00pm
Reflections on the historical use of ESAs and blood transfusions to treat patients with myelodysplastic syndromes.
January 10th 2022, 2:20pm
Experts consider shortcomings in the identification and management of myelodysplastic syndromes.
